On Tuesday, Shares of General Electric Company (NYSE:GE), lost -2.02% to $25.71.
General Electric Company declared that it has reached a contract to sell $8.5 billion of healthcare-related loans and its Healthcare Financial Services (HFS) U.S. lending business to Capital One for about $9 billion. Separately, GE has signed a contract with another buyer to sell about $600 million of HFS real estate equity investments.
“This transaction is another example of the value generated by GE Capital’s strong businesses and exceptional teams as we continue to demonstrate speed and execute on our strategy to sell most of the assets of GE Capital,” said Keith Sherin, GE Capital chairman and CEO. “We are on track to reduce our ending net investment (ENI) by $100 billion by the end of 2015 and expect to be substantially done with our exit strategy by the end of 2016,” he added.
GE Capital, Healthcare Financial Services provides financing to U.S. healthcare companies, sponsors, investors and developers across various healthcare sectors counting senior housing, hospitals, medical offices, outpatient services, pharmaceuticals and medical devices. Darren Alcus, president and CEO of HFS, will join Capital One. Capital One also will retain the HFS administration team and employees.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of Mylan N.V. (NASDAQ:MYL), declined -0.70% to $57.13, during its last trading session.
Recently, in recognition of the third anniversary of EpiPen4Schools®, Mylan N.V. (MYL), the marketer and distributor of EpiPen® (epinephrine injection) Auto-Injector, has declared the program will continue through the 2015/2016 school year. This is the only program of its kind supporting access to epinephrine in the event a person experiences a life-threatening allergic reaction, or anaphylaxis, in the school setting. Since its launch in August 2012, more than 56,000 schools have taken part in the program.
An exploratory, web-based survey of more than 6,000 schools participating in the EpiPen4Schools® program during the 2013/2014 school year found there were a total of 919 anaphylactic events among students and staff at 607 schools. In those events when an epinephrine auto-injector was used, nearly half (48.7%) were treated with an EpiPen® Auto-Injector offered by the EpiPen4Schools® program.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, Skyworks Solutions Inc. (NASDAQ:SWKS), ended its last trade with -2.26% loss, and closed at $88.97.
Skyworks Solutions, declared that executives will be presenting a company overview at two technology conferences:
- Oppenheimer Technology, Internet and Communications Conference – Wednesday, August 12, 2015 at 9:05 a.m. Eastern time from the Four Seasons Hotel in Boston
- Citi Global Technology Conference – Thursday, September 10, 2015 at 8:45 a.m. Eastern time from the Hilton New York (Midtown)
Skyworks Solutions, Inc., together with its auxiliaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
